The stock's rise snapped a four-day losing streak.
Barchart on MSN4h
ResMed's Quarterly Earnings Preview: What You Need to KnowBased in San Diego, California, ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and ...
Zacks.com on MSN9h
ResMed Gains 37.8% in a Year: What's Driving the Stock?ResMed Inc. RMD has witnessed strong momentum in the past year. Shares of the company have risen 37.8% compared with 10.7% ...
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update.Don't Miss Our New Year's ...
Shares of ResMed Inc. RMD dropped 0.09% to $228.48 Thursday, on what proved to be an all-around rough trading session for the ...
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update.Don't Miss Our New Year's ...
ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...
Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
During five years of share price growth, ResMed achieved compound earnings per share (EPS) growth of 21% per year. This EPS growth is higher than the 8% average annual increase in the share price.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback